Navigation Links
Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinson's Treatment
Date:1/25/2013

NEW BRUNSWICK, N.J., Jan. 25, 2013 /PRNewswire-USNewswire/ -- Parkinson's disease affects one million people in the United States and seven million worldwide. While L-Dopa is effective in treating the disease symptoms, the vast majority of patients taking it chronically eventually develop L-Dopa Induced Dyskinesia (LID), abnormal involuntary movements that can be disabling.

A new company, MentiNova, Inc., is exploring an oral medication that could reduce these uncontrollable, often chaotic movements in patients being treated with L-Dopa.  Foundation Venture Capital Group (FVCG), a New Jersey Health Foundation affiliate, has committed up to $500,000 to advance this research and development. 

According to James M. Golubieski , president of FVCG, the investment in MentiNova will allow the company to advance the status of its IND (Investigational New Drug) filing with the FDA and to perform clinical trials testing the efficacy of the treatment.

Dr. M. Maral Mouradian , the William Dow Lovett Professor of Neurology and Director of the Center for Neurodegenerative and Neuroimmunologic Diseases at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in Piscataway, NJ, is a co-founder of the company.

Dr. Mouradian said MentiNova's focus at this time is to use a drug that is currently clinically approved and repurpose it for the treatment of LID in patients with Parkinson's disease.

"Once we can prove positive results for using this medication for patients with Parkinson's disease suffering from L-Dopa Induced Dyskinesia, we hope to be able to test it for expanded usage in patients with other conditions that are characterized by involuntary movements such as Tourette's syndrome, Huntington's disease and Tardive Dyskinesia," said Dr. Mouradian.

Research to date has already provided in-vivo proof of principle data.

"We are very interested in this research because at this point it appears to have promising results," said Dr. George F. Heinrich , vice chair and CEO of Foundation Venture.  "We anticipate a fast IND filing and clinical trial process since the drug has already been FDA approved for another indication. This could make a tremendous difference in the quality of life for many patients who currently suffer from L-Dopa Induced Dyskinesia."

For more information, contact James M. Golubieski , president of FVCG, at (908) 731-6601 or at jgolubieski@njhf.org.

About Foundation Venture Capital Group
Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, invests in commercially viable new start-up companies developing technology by faculty at or affiliated with the University of Medicine and Dentistry of New Jersey.  In addition to MentiNova, other FVCG portfolio companies include: 

  • Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies;
  • Affineti Biologics, advancing research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine;
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
  • Durin Technologies, Inc., working to develop a blood test to diagnose Alzheimer's disease;
  • GeneAssess, Inc., a company developing a diagnostic tool for more accurate breast cancer staging;
  • Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm);
  • Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.


'/>"/>
SOURCE New Jersey Health Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asthma and Allergy Foundation of America Challenges Patients and Caregivers to Get Smart About Asthma
2. New Jersey Health Foundation Awards First Two Innovation Stage Funding Grants
3. UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community
4. Starkey Hearing Foundation Founders Bill and Tani Austin Honored by Dalai Lama After Recent Hearing Mission to India
5. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
6. USANA True Health Foundation: Musician Donates Proceeds Of Holiday Song To Charity
7. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
8. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
9. The Michael J. Fox Foundation Announces Fourth Quarter Participants in Partnering Program Between Awardees and Industry
10. Annai Systems And ThoughtWorks Develop Evidence Engine For The Clearity Foundation To Individualize Options For Treatment Of Ovarian Cancer
11. National Patient Advocate Foundation Urges Ohio Legislature to Support Oral Chemotherapy Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Massachusetts , January 19, 2017 ... ) announced that the U.S. Food and Drug Administration ... of a New Drug Application (NDA) for SHP465, a ... evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder ... on or around June 20, 2017, the designated Prescription ...
(Date:1/19/2017)... Pfizer joins Astex, AstraZeneca, ... Consortium   Major research investment to ...   The Milner Therapeutics Institute today ... a partner to the Milner Therapeutics Consortium. Pfizer has ... transfer of materials between industry and academia and allocation ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Bump eRaiser, recently attended the January ECRM Trade Show in Hilton Head, SC, where ... an international reputation for the quality of its beauty and wellness products. At this ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/20/2017)... ... , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, ... on wheels, it can be wheeled out of the way and stored when not in ... "We have transformed the feedback from customers into specific enhancements and created a new product ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
Breaking Medicine News(10 mins):